Autonomix Medical | 10-Q: FY2026 Q2 Revenue: USD 0

Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -1.38.

EBIT: As of FY2026 Q2, the actual value is USD -7.617 M.

Segment Revenue

• The company did not generate any revenue for the three and six months ended September 30, 2025, and 2024, respectively.

Operational Metrics

• Net Loss: The net loss for the three months ended September 30, 2025, was $7.5 million, compared to $2.8 million for the same period in 2024. For the six months ended September 30, 2025, the net loss was $10.8 million, compared to $5.5 million in 2024.
• Operating Expenses: Total operating expenses for the three months ended September 30, 2025, were $7.5 million, an increase of 166% from $2.8 million in 2024. For the six months ended September 30, 2025, operating expenses were $11.0 million, up 96% from $5.6 million in 2024.
• Research and Development: R&D expenses increased by 102% to $2.4 million for the three months ended September 30, 2025, and by 86% to $4.0 million for the six months ended September 30, 2025.
• General and Administrative: G&A expenses increased by 211% to $5.2 million for the three months ended September 30, 2025, and by 102% to $7.0 million for the six months ended September 30, 2025.

Cash Flow

• Operating Cash Flow: Net cash used in operating activities was $6.4 million for the six months ended September 30, 2025, compared to $3.4 million in 2024.
• Free Cash Flow: Not explicitly stated, but the net decrease in cash and cash equivalents was $1.7 million for the six months ended September 30, 2025.

Unique Metrics

• Stock-Based Compensation: Significant increases in stock-based compensation expenses were noted, primarily due to stock option cancellation agreements, contributing to the rise in both R&D and G&A expenses.

Future Outlook and Strategy

• Core Business Focus: The company is focused on advancing its catheter-based technology for sensing and treating disorders of the nervous system, with ongoing clinical trials and product development efforts. The company completed a first-in-human proof-of-concept study and is expanding its clinical trials to include additional cancer-related pain indications.
• Non-Core Business: The company has entered into agreements to potentially raise additional capital through the sale of common stock, which is crucial for funding ongoing operations and development efforts.
• Priority: The company estimates it will require additional financing of approximately $30 to $36 million to fund operations to commercialization of its first indication.